medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2008, Number 4

<< Back Next >>

Rev Invest Clin 2008; 60 (4)

Conceptos actuales sobre la fisiopatología y diagnóstico de la encefalopatía hepática

Torre A

Language: Spanish
References: 60
Page: 321-331
PDF size: 222.34 Kb.


Text Extraction

No abstract


REFERENCES

  1. Torre A, Terra C, Arroyo V. Encefalopatía porto-sistémica: Patogénesis y nuevos tratamientos. En: Uribe ME, Florencia VV (eds.). Problemas Clínicos en Hepatología. México: Editorial Masson Doyma; 2005, p. 153-66.

  2. Quero-Guillen JC, Herrerías-Gutiérrez JM. Diagnostic methods in hepatic encephalopathy. Clin Chim Acta 2006; 365: 1-8.

  3. Lizardi-Cervera JL, Almeda P, Guevara L. Hepatic encephalopathy: a review. Ann Hepatol 2003; 2: 122-30.

  4. Torre-Delgadillo A, Guerrero-Hernández I, Uribe M. Encefalopatía hepática: características, diagnóstico e implicaciones clínicas. Rev Gastroenterol Mex 2006; 71: 63-70.

  5. Ferenci P, Lockwood A, Mullen K, et al. Hepatic encephalopahty. Definition, nomenclature, diagnosis and quantification: final report of the working party at the 11th World Congresses of Gastroenterology. Viena, 1998. Hepatology 2002; 35: 716-21.

  6. Quero JC, Schalm S. Subclinical hepatic encephalopathy. Semin Live Dis 1996; 16: 321-8.

  7. Dhiman RH, Saraswat VA, Verma M, et al. Figure connection test: a universal test for assessment of mental state. J Gastroenterol Hepatol 1995; 10: 14-23.

  8. Ong JP, Aggarwal A, Krieger D, et al. Correlation between ammonia levels and the severity of hepatic encephalopathy. Am J Med 2003; 114: 188-93.

  9. Yurdaydin C. Blood ammonia determination in cirrhosis: still confusing after all these years? Hepatology 2003; 38: 1307-10.

  10. Alman RW, Ehrmantraut WR, Fazekas JF, et al. Cerebral metabolism in hepatic insufficiency. Am J Med 1956; 21: 843-9.

  11. Lockwood AH, Yap EW, Wong WH. Cerebral ammonia metabolism in patients with severe liver disease and minimal hepatic encephalopathy. J Cereb Blood Flow Metab 1991; 11: 337-41.

  12. Norenberg MD. The role of astrocytes in hepatic encephalopathy. Neurochem Pathol 1987; 6: 13-33.

  13. Gregorios JB, Mozes LW, Norenberg MD. Morphologic effects of ammonia on primary astrocytes cultures. Electron microscopic studies. J Neuropathol Exp Neurol 1985; 44: 404-14.

  14. Shawcross D, Deutz NEP, Olde Damink SWN, et al. Hepatic encephalopathy in liver failure. A multiorgan perspective. In: Arroyo V, Forns X, García Pagan JC, Rodés J (eds.). Progress in the treatment of liver diseases; 2005, p. 51-60.

  15. Romero MG, Bautista JD, Grande L, et al. Nuevos conceptos en la fisiopatología de la encefalopatía hepática y perspectivas terapéuticas. Gastroenterol Hepatol 2004; 27(Suppl. 1): 40-8.

  16. Wolpert E, Phillips SF, Summerskill WH. Ammonia production in the human colon. Effects of cleasing, neomycin and acetohydroxamic acid. N Engl J Med 1970; 283: 159-64.

  17. Olde Dammik SW, Jalan R, Redhead DN, et al. Interorgan ammonia and amino acid metabolism in metabolically stable patients with cirrhosis and TIPS. Hepatology 2002; 36: 1163-71.

  18. Romero-Gómez M, Grande L, Camacho I, et al. Altered response to oral glutamine challenge as prognostic factor for overt episodes in patients with minimal hepatic encephalopathy. J Hepatol 2002; 37: 781-7.

  19. Grande L, Ramos Guerrero R, Collantes de Terán L, et al. Actividad glutaminasa mitocondrial del enterocito en la encefalopatía hepática incipiente. Gastroenterol Hepatol 2003; 26(Suppl. 2): 67.

  20. Lockwood AH, McDonald JM, Reiman RE, et al. The dynamics of ammonia metabolism in man. Effects of liver disease and hyperammonemia. J Clin Invest 1979; 63: 449-60.

  21. Good DW, DuBose TD Jr. Ammonia transport by early and late proximal convulated tubule of rat. J Clin Invest 1987; 79: 684-91.

  22. Hamm LL, Simon EE. Ammonia transport in the proximal tubule. Miner Electrolyte Metab 1990; 16: 283-90.

  23. Norenberg MD, Martínez-Hernández A. Fine structural localization of glutamine synthetase in astrocytes of rat brain. Brain Res 1979; 161: 303-10.

  24. Stewart CA, Cerhan J. Hepatic encephalopathy: a dynamic or static condition. Metab Brain Dis 2005; 20: 193-204.

  25. Vaquero J, Butterworth RF. The brain glutamate system in liver failure. J Neurochem 2006; 98: 661-9.

  26. Muckart DJ, Bhagwanjee S. Definitions of the systemic inflammatory response syndrome and allied disorders in relation to critically injured patients. Crit Cara Med 1997; 25: 1789-95.

  27. Hu S, Sheng WS, Ehrilich LC, et al. Cytokine effect on glutamate uptake by human astrocytes. Neuroimmunomodulation 2000; 7: 153-9.

  28. Bender AS, Rivera IV, Norenberg MD. Tumor necrosis factor induces astrocyte swelling. Trans Am Neurochem 1992; 23: 113.

  29. Jones EA. Ammonia the GABA neurotransmitter system, and hepatic encephalopathy. Metab Brain Dis 2002; 17: 275-81.

  30. Lambert JJ, Belelli D, Hill-Venning C, et al. Neuroesteroids and GABA A receptor function. Trends Phamacol Sci 1995; 16: 295-303.

  31. Butterworth RF. Glutamate transporters in hyperammonemia. Neurochem Intern 2002; 41: 81-5.

  32. Butterworth RF. Neurotransmitter dysfunction in hepatic encephalopathy: new approaches and new findings. Metab Brain Dis 2001: 16; 55-65.

  33. Weissenborn K, Ruckert N, Hecker H, et al. The number connection test A and B interindividual variability and use for the assessment of early hepatic encephalopathy. J Hepatol 1998; 28: 646-53.

  34. Conn HO. Trailmaking and number connection tests in the assessment of mental state in portal systemic encephalopathy. Am J Dig Dis 1977; 22: 541-50.

  35. Weissenborn K, Ennen JC, Rückert N, et al. Neuropsychological characterization of hepatic encephalopathy. J Hepatol 2001; 34: 768-73.

  36. Amodio P, Marchett P, del Piccolo F, et al. Study on the Sternberg paradigm in cirrhotic patients without hepatic encephalopathy. Metab Brain Dis 1998; 13: 159-72.

  37. Kircheis G, Fleig WE, Gortelmeyer R, et al. Assessment of low grade encephalopathy: a critical analysis. J Hepatol 2007; 47(5): 642-50.

  38. Kircheis G, Wettstein M, Timmermann L, et al. Critical flicker frequency for quantification of low-grade hepatic encephalopathy. Hepatology 2002; 35(2): 357-66.

  39. Niedermeyer E. Metabolic central nervous system disorders. In: Niedermeyer E, Lopes Da Silva F (eds.). Electroencephalography. Basis Principles, Clinical Applications, and Related Fields. 4th Ed. Baltimore: Williams and Wilkins; 1994, p. 416-31.

  40. Kullmann F, Hollerbach S, Holstege A, et al. Subclinical hepatic encephalopathy: The diagnostic value of evoked potentials. J Hepatol 1995; 22(1): 101-10.

  41. Amodio P, Marchetti P, DelPiccolo F, et al. Spectral versus visual EEG analysis in mild hepatic encephalopathy. Clin Neurophysiol 1999; 110: 1334-44.

  42. Amodio P, del Piccolo F, Petteno E, et al. Prevalence and prognostic value of quantified electroencephalogram (EEG) alterations in cirrhotic patients. J Hepatol 2001; 35: 37-45.

  43. Saxena N, Bathia M, Joshi YK, et al. Auditory P300 event related potentials and number connection test for the diagnosis of subclinical hepatic encephalopathy in patients with cirrhosis of liver. A follow up study. J Gastroenterol Hepatol 2001; 16: 322-7.

  44. Lookwood AH, Weissenborn K, Butterworth RF. An image of the brain in patient with liver disease. Curr Opin Neurol 1997; 10: 525-33.

  45. Spahr L, Vingerhoets F, Lazayras F, et al. Magnetic resonance imaging and proton spectroscopic alterations correlate with parkinsonian signs in patients with cirrhosis. Gastroenterology 2000; 119: 774-81.

  46. Rovira A, Córdoba J, Sanpedro F, et al. Normalization of T2 signal abnormalities in hemispheric white matter with liver transplant. Neurology 2002; 59: 335-41.

  47. Seery JP, Taylor-Robinson S. The application of magnetic resonance spectroscopy to the study of hepatic encephalopathy. J Hepatol 1996; 25: 988-98.

  48. Butterworth RF. Pathogenesis of hepatic encephalopathy: new insights from neuroimaging and molecular studies. J Hepatol 2003; 39: 278-85.

  49. Loockwood AH, Weissenborn K, Bokementer M, et al. Correlation between cerebral glucose metabolism and neuropsychological tests performance in non-alcoholic cirrhotics. Metab Brain Dis 2002; 17: 29-40.

  50. Dam M, Burra P, Tedaschi U, et al. Regional cerebral blood flow changes in patients with cirrhosis assesses with 99mTc-HM-PAQ single photon emission computed tomography: effect of liver transplantation. J Hepatol 1998; 29: 78-84.

  51. Ross BD, Danielsen ER, Blum S. Proton magnetic resonance spectroscopy: the new gold standard for diagnosis of clinical and subclinical hepatic encephalopathy? Dig Dis 1996; 14(Suppl. 1): 30-9.

  52. Ross BD, Jacobson S, Villamil F, et al. Subclinical hepatic encephalopathy: proton MR-spectroscopic abnormalities. Radiology 1994; 193: 457-63.

  53. Mechtcheriakov S, Shocke M, Kugener A, et al. Chemical shoft magnetic resonance spectroscopy of congulate grey matter in patients with minimal hepatic encephalopathy. Neuroradiology 2005; 47: 27-34.

  54. Weissenborn K, Heidenreich S, Giewekemeyer K, et al. Memory function in early hepatic encephalopathy. J of Hepatol 2003; 39: 320-5.

  55. Catafau AM, Kuliesevsky J, Berna L, et al. Relationship between cerebral perfusion in frontal-limbic-basal ganglia circuits and neuropsychologic impairment in patients with subclinical hepatic encephalopathy. J Nucl Med 2000; 41: 405-10.

  56. Posner MI, Petersen SE. The attention system of the human brain. Ann Rev Neurosci 1990; 13: 25-42.

  57. Posner MI. Attention in cognitive neuroscience: An overview In: Gazzaniga MS. The cognitive neuroscience. Cambridge Massachusetts; MIT Press; 1995, p. 615-24.

  58. Trzepacz PT, Tarter RE, Shah A, et al. SPECT scan and cognitive findings in subclinical hepatic encephalopathy. J Neuropsychiatry Clin Neurosci 1994; 6: 170-5.

  59. Lockwood AH, Murphy BW, Donnelly KZ, et al. Positron emission tomographic localization of abnormalities of brain metabolism in patients with minimal hepatic encephalopathy. Hepatology 1993; 18: 1061-8.

  60. Méndez-Sánchez N, Villa, Chávez-Tapia N, et al. Trends in liver prevalence in Mexico from 2005 to 2050 through mortality data. Annals of Hepatology 2005; 4(1): 52-5.




2020     |     www.medigraphic.com